We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
1
DELISTED
Celgene Corp
CELG
$146M 6.38%
1,473,710
– –
AMGN icon
2
Amgen
AMGN
$209B
$122M 5.34%
632,287
-97,371
-13% -$18.7M
GILD icon
3
Gilead Sciences
GILD
$163B
$116M 5.07%
1,833,982
-2,130
-0.1% -$139K
JNJ icon
4
Johnson & Johnson
JNJ
$617B
$106M 4.62%
818,227
-71,777
-8% -$9.46M
MRK icon
5
Merck
MRK
$321B
$102M 4.45%
1,269,530
+207,178
+20% +$16.6M
VRTX icon
6
Vertex Pharmaceuticals
VRTX
$122B
$82.5M 3.6%
487,234
-2,500
-0.5% -$442K
PFE icon
7
Pfizer
PFE
$142B
$76M 3.31%
2,228,479
+48,528
+2% +$1.76M
ILMN icon
8
Illumina
ILMN
$31B
$73.4M 3.2%
247,891
+43,863
+21% +$12.9M
UNH icon
9
UnitedHealth
UNH
$383B
$73.3M 3.2%
337,283
+13,150
+4% +$3.17M
BIIB icon
10
Biogen
BIIB
$30.7B
$60.1M 2.62%
257,939
+33,249
+15% +$7.74M
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$44.5M 1.94%
453,887
+53,873
+13% +$6.07M
REGN icon
12
Regeneron Pharmaceuticals
REGN
$77.4B
$44.3M 1.93%
159,658
-7,310
-4% -$2.16M
MDT icon
13
Medtronic
MDT
$110B
$43.4M 1.89%
399,370
-80,665
-17% -$8.42M
BMY icon
14
Bristol-Myers Squibb
BMY
$132B
$37.4M 1.63%
738,044
– –
CVS icon
15
CVS Health
CVS
$134B
$34.1M 1.49%
540,286
-35,115
-6% -$2.08M
ZTS icon
16
Zoetis
ZTS
$31.9B
$31M 1.35%
249,024
+440
+0.2% +$53.1K
ABBV icon
17
AbbVie
ABBV
$455B
$30.3M 1.32%
400,016
+66,700
+20% +$4.57M
ISRG icon
18
Intuitive Surgical
ISRG
$126B
$30M 1.31%
166,425
-600
-0.4% -$104K
INCY icon
19
Incyte
INCY
$24.9B
$29.2M 1.28%
393,730
-117,203
-23% -$9.47M
ELV icon
20
Elevance Health
ELV
$81.6B
$29.1M 1.27%
121,132
+17,676
+17% +$4.84M
ABT icon
21
Abbott
ABT
$183B
$27M 1.18%
322,513
-181,635
-36% -$15.4M
TMO icon
22
Thermo Fisher Scientific
TMO
$214B
$26M 1.13%
89,310
-46,888
-34% -$13.4M
SYK icon
23
Stryker
SYK
$133B
$25.6M 1.12%
118,520
+15,570
+15% +$3.34M
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$24.8M 1.08%
289,925
– –
AGN
25
DELISTED
Allergan plc
AGN
$24.4M 1.07%
145,281
+1,000
+0.7% +$163K
1
2 3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.